Phase 2 study of CXA-101 for the treatment of urinary tract infections

Calixa Therapeutics announced the initiation of a Phase 2 trial of CXA-101 in patients with complicated urinary tract infections. This multi-center, randomized study is anticipated to enroll approximately 120 patients and will compare the efficacy and safety of CXA-101 with the current standard of therapy. The primary efficacy endpoint for this study is microbiological outcome at the test-of-cure visit between six to nine days after the end of therapy.

CXA-101 is a new broad-spectrum, parenteral cephalosporin antibiotic with in vitro and in vivo activity against gram-negative pathogens such as Pseudomonas aeruginosa, including drug resistant isolates.

For more information call (858) 480-2420 or visit www.calixainc.com.